NCT00887406View on ClinicalTrials.gov

Study of GSK961081 in Healthy Volunteer Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 7, 2005

Primary Completion Date

October 4, 2006

Study Completion Date

October 4, 2006

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK961081 15mcg SD

Single dose delivered via solution for nebulisation

DRUG

GSK961081 3mcg SD

single dose delivered via nebulsier

DRUG

GSK961081 50mcg SD

single dose delivered via solution for nebulisation

DRUG

Placebo SD

single dose via nebuliser

DRUG

GSK961081 100mcg SD

single dose delivered via solution for nebulisation

DRUG

GSK961081 200mcg SD

single dose via nebuliser

DRUG

GSK961081 300mcg SD

single dose via nebuliser

DRUG

GSK961081 100mcg RD

repeat dose via nebuliser

DRUG

GSK961081 300mcg RD

repeat dose vai nebuliser

DRUG

Placebo RD

repeat dose via nebuliser

Trial Locations (1)

Unknown

GSK Investigational Site, London

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Theravance Biopharma

INDUSTRY

NCT00887406 - Study of GSK961081 in Healthy Volunteer Subjects | Biotech Hunter | Biotech Hunter